BRIDGEND, WALES, 23 September 2025 – Molomix Bioscience Ltd, a UK-based biotechnology company deploying a revolutionary decentralised, AI-powered diagnostics platform, today announced the strategic appointments of Adam James-Wilkinson as Chief Revenue Officer and Dr. Mark Darbyshire as Chief Medical Officer. These key hires will accelerate the company’s mission to make advanced molecular analysis accessible and affordable, tackling systemic challenges in both scientific research and healthcare.
The appointments come as Molomix prepares for the phased commercial launch of its Molecular Diagnostics Platform (MDP), a versatile “lab-on-a-chip” system offered with a disruptive zero-capital expenditure, “as a Service” business model.
“We are thrilled to welcome Adam and Mark to the Molomix leadership team,” said Stephen Pickett, Chief Executive Officer. “Adam’s proven expertise in scaling socially-focused technology organisations is exactly what we need to drive our commercial strategy and bring our unique zero-CapEx model to the research and industrial markets. Simultaneously, Mark’s extensive frontline experience provides invaluable clinical insight that will be critical as we prepare to tackle the profound challenges in UK healthcare, from crippling diagnostic delays to health inequity. Their combined expertise will be instrumental as we execute our strategic roadmap.”
Adam James-Wilkinson, Chief Revenue Officer
As Chief Revenue Officer, Adam James-Wilkinson will be responsible for leading the company’s entire revenue generation strategy, building the sales and marketing functions, and driving the market adoption of the MDP. With over 20 years of experience, Adam has a distinguished track record of selling SaaS solutions and services across the charity, Government, and healthcare sectors. At his previous company, Connect Assist, he and Stephen Pickett were part of a leadership team that successfully undertook a Management Buy-Out (MBO) and subsequent very successful exit four years later, one year ahead of target. He will be utilising these skills to scale Molomix’s commercial operations and support its customers to fundamentally transform their own service delivery, helping them to radically speed up analysis, slash costs through the zero-CapEx model, and eliminate the risks inherent in traditional laboratory workflows.
“I’m delighted to join a company so perfectly aligned with my personal and professional objectives,” said Adam James-Wilkinson. “Molomix isn’t just selling a product; it’s delivering a new, more equitable paradigm for science and medicine. The ‘as a Service’ model is a game-changer that removes the primary cost barrier to adopting state-of-the-art technology, and I am excited to build the commercial engine that will bring this powerful platform to labs across the UK and Europe.”
Dr. Mark Darbyshire, Chief Medical Officer
As Chief Medical Officer, Dr. Mark Darbyshire will provide overall medical and clinical leadership, ensuring Molomix’s solutions are aligned with the needs of patients and clinicians. A highly experienced General Practitioner and former British Army Major, Dr. Darbyshire has a deep, firsthand understanding of the diagnostic bottlenecks Molomix aims to eliminate. His experience in battlefield medicine and as a GP in highly remote locations has given him direct insight into the challenges of managing antimicrobial resistance (AMR) and diagnosing difficult diseases where rapid results are critical.
“Throughout my career, I’ve seen how diagnostic delays and a lack of access to advanced technology can impact patient outcomes,” said Dr. Mark Darbyshire. “Molomix’s platform offers a direct solution to these challenges by bringing rapid, precise molecular analysis to the point-of-need. The opportunity to help guide the clinical strategy of a technology that can genuinely reduce health inequalities and empower frontline clinicians is incredibly compelling.”
Molomix is preparing for the commercial launch of its MDP into the UK research, veterinary, and forensics markets in 2026. The company plans to later expand into the clinical diagnostics sector by introducing SiGenex’s innovative platform with its in-built Next-Generation Sequencer (NGS).
About Molomix Bioscience Ltd
Molomix Bioscience is a UK-based biotechnology company with a mission to empower its partners to solve humanity’s most pressing scientific and health challenges. By deploying a revolutionary decentralised, AI-powered platform, Molomix brings the world’s most advanced molecular and multiomic technologies directly to the point-of-need, making them accessible and affordable through a disruptive “as a Service” approach.
Contact Information:
Stephen Pickett
Chief Executive Officer
Molomix Bioscience Ltd
Tel: +44 7825 022518
E-mail: [email protected]
Web: https://molomix.co.uk
– ENDS –